Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo

George J. Christ, Nancy Day, Cristian Santizo, Yoshi Sato, Weixin Zhao, Theresa Sclafani, Ron Bakal, Masha Salman, Kelvin Davies, Arnold Melman

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

The ability of gene transfer with the pore-forming subunit of the human maxi-K channel (hSlo) to ameliorate the decline in erectile capacity commensurate with 12-24 wk of streptozotocin (STZ)-diabetes was examined in 181 Fischer-344 rats. A 2-mo period of STZ-diabetes was induced before gene transfer, and erectile capacity was evaluated by measuring the intracavernous pressure response (ICP) to cavernous nerve (CN) stimulation (ranging from 0.5 to 10 mA). In the first series of experiments, ANOVA revealed increased CN-stimulated ICP responses at 1 and 2 mo postinjection of 100 μg pcDNA-hSlo compared with control values. A second series of experiments further examined the dose dependence and duration of gene transfer. The ICP response to submaximal (0.5 mA) and maximal (10 mA) nerve stimulation was evaluated 3 or 4 mo postinjection of a single dose of pcDNA-hSlo ranging from 10 to 1,000 μg. ANOVA again revealed that hSlo overexpression was associated with increased CN-stimulated ICP responses compared with responses in corresponding control animals. Histological studies revealed no immune response to the presence of hSlo. PCR analysis documented that expression of both plasmid and transcript were largely confined to the corporal tissue. In the third series of pharmacological experiments, hSlo gene transfer in vivo was associated with iberiotoxin-sensitive relaxation responses to sodium nitroprusside in corporal tissue strips in vitro. The latter data indicate that gene transfer produces functional maxi-K channels that participate in the modulation of corporal smooth muscle cell tone. Taken together, these observations suggest a fundamental diabetes-related change in corporal myocyte maxi-K channel regulation, expression, or function that may be corrected by expression of recombinant hSlo.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume287
Issue number4 56-4
DOIs
StatePublished - Oct 2004

Fingerprint

Streptozocin
Large-Conductance Calcium-Activated Potassium Channels
Complementary DNA
Injections
Pressure
Experimental Diabetes Mellitus
Genes
Analysis of Variance
Inbred F344 Rats
Nitroprusside
Muscle Cells
Smooth Muscle Myocytes
Plasmids
Pharmacology
Polymerase Chain Reaction

Keywords

  • Corporal smooth muscle
  • Erectile dysfunction
  • Gene transfer
  • Maxi-K channel
  • Myocytes

ASJC Scopus subject areas

  • Physiology

Cite this

Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. / Christ, George J.; Day, Nancy; Santizo, Cristian; Sato, Yoshi; Zhao, Weixin; Sclafani, Theresa; Bakal, Ron; Salman, Masha; Davies, Kelvin; Melman, Arnold.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 287, No. 4 56-4, 10.2004.

Research output: Contribution to journalArticle

Christ, George J. ; Day, Nancy ; Santizo, Cristian ; Sato, Yoshi ; Zhao, Weixin ; Sclafani, Theresa ; Bakal, Ron ; Salman, Masha ; Davies, Kelvin ; Melman, Arnold. / Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. In: American Journal of Physiology - Heart and Circulatory Physiology. 2004 ; Vol. 287, No. 4 56-4.
@article{6d99d46f59604c5c9f4458fe1f874de7,
title = "Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo",
abstract = "The ability of gene transfer with the pore-forming subunit of the human maxi-K channel (hSlo) to ameliorate the decline in erectile capacity commensurate with 12-24 wk of streptozotocin (STZ)-diabetes was examined in 181 Fischer-344 rats. A 2-mo period of STZ-diabetes was induced before gene transfer, and erectile capacity was evaluated by measuring the intracavernous pressure response (ICP) to cavernous nerve (CN) stimulation (ranging from 0.5 to 10 mA). In the first series of experiments, ANOVA revealed increased CN-stimulated ICP responses at 1 and 2 mo postinjection of 100 μg pcDNA-hSlo compared with control values. A second series of experiments further examined the dose dependence and duration of gene transfer. The ICP response to submaximal (0.5 mA) and maximal (10 mA) nerve stimulation was evaluated 3 or 4 mo postinjection of a single dose of pcDNA-hSlo ranging from 10 to 1,000 μg. ANOVA again revealed that hSlo overexpression was associated with increased CN-stimulated ICP responses compared with responses in corresponding control animals. Histological studies revealed no immune response to the presence of hSlo. PCR analysis documented that expression of both plasmid and transcript were largely confined to the corporal tissue. In the third series of pharmacological experiments, hSlo gene transfer in vivo was associated with iberiotoxin-sensitive relaxation responses to sodium nitroprusside in corporal tissue strips in vitro. The latter data indicate that gene transfer produces functional maxi-K channels that participate in the modulation of corporal smooth muscle cell tone. Taken together, these observations suggest a fundamental diabetes-related change in corporal myocyte maxi-K channel regulation, expression, or function that may be corrected by expression of recombinant hSlo.",
keywords = "Corporal smooth muscle, Erectile dysfunction, Gene transfer, Maxi-K channel, Myocytes",
author = "Christ, {George J.} and Nancy Day and Cristian Santizo and Yoshi Sato and Weixin Zhao and Theresa Sclafani and Ron Bakal and Masha Salman and Kelvin Davies and Arnold Melman",
year = "2004",
month = "10",
doi = "10.1152/ajpheart.00792.2003",
language = "English (US)",
volume = "287",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "4 56-4",

}

TY - JOUR

T1 - Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo

AU - Christ, George J.

AU - Day, Nancy

AU - Santizo, Cristian

AU - Sato, Yoshi

AU - Zhao, Weixin

AU - Sclafani, Theresa

AU - Bakal, Ron

AU - Salman, Masha

AU - Davies, Kelvin

AU - Melman, Arnold

PY - 2004/10

Y1 - 2004/10

N2 - The ability of gene transfer with the pore-forming subunit of the human maxi-K channel (hSlo) to ameliorate the decline in erectile capacity commensurate with 12-24 wk of streptozotocin (STZ)-diabetes was examined in 181 Fischer-344 rats. A 2-mo period of STZ-diabetes was induced before gene transfer, and erectile capacity was evaluated by measuring the intracavernous pressure response (ICP) to cavernous nerve (CN) stimulation (ranging from 0.5 to 10 mA). In the first series of experiments, ANOVA revealed increased CN-stimulated ICP responses at 1 and 2 mo postinjection of 100 μg pcDNA-hSlo compared with control values. A second series of experiments further examined the dose dependence and duration of gene transfer. The ICP response to submaximal (0.5 mA) and maximal (10 mA) nerve stimulation was evaluated 3 or 4 mo postinjection of a single dose of pcDNA-hSlo ranging from 10 to 1,000 μg. ANOVA again revealed that hSlo overexpression was associated with increased CN-stimulated ICP responses compared with responses in corresponding control animals. Histological studies revealed no immune response to the presence of hSlo. PCR analysis documented that expression of both plasmid and transcript were largely confined to the corporal tissue. In the third series of pharmacological experiments, hSlo gene transfer in vivo was associated with iberiotoxin-sensitive relaxation responses to sodium nitroprusside in corporal tissue strips in vitro. The latter data indicate that gene transfer produces functional maxi-K channels that participate in the modulation of corporal smooth muscle cell tone. Taken together, these observations suggest a fundamental diabetes-related change in corporal myocyte maxi-K channel regulation, expression, or function that may be corrected by expression of recombinant hSlo.

AB - The ability of gene transfer with the pore-forming subunit of the human maxi-K channel (hSlo) to ameliorate the decline in erectile capacity commensurate with 12-24 wk of streptozotocin (STZ)-diabetes was examined in 181 Fischer-344 rats. A 2-mo period of STZ-diabetes was induced before gene transfer, and erectile capacity was evaluated by measuring the intracavernous pressure response (ICP) to cavernous nerve (CN) stimulation (ranging from 0.5 to 10 mA). In the first series of experiments, ANOVA revealed increased CN-stimulated ICP responses at 1 and 2 mo postinjection of 100 μg pcDNA-hSlo compared with control values. A second series of experiments further examined the dose dependence and duration of gene transfer. The ICP response to submaximal (0.5 mA) and maximal (10 mA) nerve stimulation was evaluated 3 or 4 mo postinjection of a single dose of pcDNA-hSlo ranging from 10 to 1,000 μg. ANOVA again revealed that hSlo overexpression was associated with increased CN-stimulated ICP responses compared with responses in corresponding control animals. Histological studies revealed no immune response to the presence of hSlo. PCR analysis documented that expression of both plasmid and transcript were largely confined to the corporal tissue. In the third series of pharmacological experiments, hSlo gene transfer in vivo was associated with iberiotoxin-sensitive relaxation responses to sodium nitroprusside in corporal tissue strips in vitro. The latter data indicate that gene transfer produces functional maxi-K channels that participate in the modulation of corporal smooth muscle cell tone. Taken together, these observations suggest a fundamental diabetes-related change in corporal myocyte maxi-K channel regulation, expression, or function that may be corrected by expression of recombinant hSlo.

KW - Corporal smooth muscle

KW - Erectile dysfunction

KW - Gene transfer

KW - Maxi-K channel

KW - Myocytes

UR - http://www.scopus.com/inward/record.url?scp=4744354628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4744354628&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00792.2003

DO - 10.1152/ajpheart.00792.2003

M3 - Article

C2 - 15371262

AN - SCOPUS:4744354628

VL - 287

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 4 56-4

ER -